42 completed, 7 terminated, 6 recruiting, 6 unknown. 63 Phase 1, 20 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 63 | Completed 42, Terminated 7, Recruiting 6, Unknown 6, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 20 | Completed 15, Unknown 3, Recruiting 1, Withdrawn 1 |
Follow GM-CSF: new trials by email Literature Review of GM-CSF trials Research Report on GM-CSF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF - Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 42 | 2026-03-04 | 2026-04-03 |
| Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | Phase 1 | Recruiting | David Avigan | 30 | 2026-02-12 | 2026-05-05 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM DC/MM Fusion Vaccine, GM-CSF - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2026-01-30 | 2026-05-08 |
| Tebentafusp-tebn With LDT in Metastatic UM Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | Thomas Jefferson University | 109 | 2025-10-15 | 2026-07-21 |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2025-01-31 | 2026-05-07 |
| Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection iNeo-Vac-P01, GM-CSF - Resectable Esophageal Cancer | Phase 1 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 27 | 2021-12-02 | 2025-12-02 |
| GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery GM-CSF, fosfomycin and metronidazole - Pouchitis | Phase 1 / Phase 2 | Unknown | Zealand University Hospital | 18 | 2021-09-06 | 2023-01-26 |
| IBI188 Combination Therapy in Solid Tumors IBI188, GM-CSF, Cisplatin/Carboplatin - Solid Tumors, Lung Adenocarcinoma | Phase 1 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 9 | 2021-05-25 | 2022-10-04 |
| Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy iNeo-Vac-P01, GM-CSF - Resectable Pancreatic Cancer | Phase 1 | Unknown | Zhejiang Provincial People's Hospital | 20 | 2021-03-30 | 2021-11-16 |
| Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection AV-COVID-19, GM-CSF - COVID-19 | Phase 1 | Completed | Aivita Biomedical, Inc. | 27 | 2020-12-07 | 2021-12-16 |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Abemaciclib, Irinotecan, Temozolomide - Relapsed Solid Tumor, Refractory Solid Tumor | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 47 | 2020-11-09 | 2026-03-02 |
| Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors iNeo-Vac-P01, GM-CSF, PD-1 - Advanced Malignant Solid Tumor | Phase 1 | Unknown | Sir Run Run Shaw Hospital | 30 | 2020-09-03 | 2021-04-28 |
| Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers galinpepimut-S, pembrolizumab, Montanide - Acute Myelogenous Leukemia, Ovarian Cancer | Phase 1 / Phase 2 | Completed | Sellas Life Sciences Group | 26 | 2019-09-30 | 2024-11-19 |
| Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma Galinpepimut-S, Nivolumab, Sargramostim - Mesothelioma, Pleural Mesothelioma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2019-07-24 | 2025-05-13 |
| A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ Granulocyte-Macrophage Colony-Stimulating Factor, Multi-epitope HER2 Peptide Vaccine H2NVAC, Therapeutic Conventional Surgery - Breast Ductal Carcinoma In Situ | Phase 1 | Recruiting | Mayo Clinic | 43 | 2019-06-27 | 2026-03-05 |
| UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma UV1, GM-CSF - Malignant Melanoma | Phase 1 | Completed | Ultimovacs ASA | 30 | 2018-07-09 | 2024-08-22 |
| First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 Placebo, GSK3358699, GM-CSF - Arthritis, Rheumatoid | Phase 1 | Terminated | GlaxoSmithKline | 48 | 2018-03-13 | 2020-12-02 |
| Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor iNeo-Vac-P01, GM-CSF - Advanced Malignant Solid Tumor | Phase 1 | Unknown | Sir Run Run Shaw Hospital | 30 | 2018-02-07 | 2021-11-16 |
| Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer iNeo-Vac-P01, GM-CSF - Pancreatic Cancer, Pancreatic Carcinoma | Phase 1 | Completed | Zhejiang Provincial People's Hospital | 7 | 2017-10-24 | 2021-11-16 |
| REO13 Melanoma With of Without GM-CSF Reolysin, GM-CSF - Melanoma, Cancer of Skin | Phase 1 / Phase 2 | Withdrawn | University of Leeds | 2017-10-01 | 2018-05-04 |
Showing 20 of 63. Sign in to see all of them.
Melanoma (11) · Breast Neoplasms (5) · Multiple Myeloma (5) · Lymphoma (4) · Neuroblastoma (4) · Breast Neoplasms, Male (3) · Carcinoma, Ovarian Epithelial (3) · Colorectal Neoplasms (3) · Leukemia (3) · Leukemia, Myeloid, Acute (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Uveal Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2)
National Cancer Institute (NCI) (7) · David Avigan (3) · University of Washington (3) · Mayo Clinic (2) · Roger Williams Medical Center (2) · Roswell Park Cancer Institute (2) · Sellas Life Sciences Group (2) · Sir Run Run Shaw Hospital (2) · Ultimovacs ASA (2) · University Hospital Tuebingen (2) · University of Virginia (2) · Zhejiang Provincial People's Hospital (2) · Ahmad Tarhini (1) · Aivita Biomedical, Inc. (1) · Barbara Ann Karmanos Cancer Institute (1)
United States (45) · China (6) · United Kingdom (4) · Germany (3) · Australia (2) · Belgium (2) · Spain (2) · Sweden (2) · Bulgaria (1) · Denmark (1) · France (1) · Hungary (1) · Indonesia (1) · Italy (1) · Japan (1)
David Avigan, MD (2) · John Marshall (2) · Kunle Odunsi (2) · Abby Maizel, MD, PhD (1) · Abby Maizel, MD,PhD (1) · Ahmad A. Tarhini, MD, MS (1) · Al Barqawi (1) · Amy C. Degnim, M.D. (1) · Andrea Mayer-Mokler (1) · Andrew Gilman (1) · Arnulf Stenzl, Prof. (1) · B. Smith (1) · Ba Yi (1) · Brandon M. Triplett, MD (1)
PMID 33986124, PMID 11359672, PMID 18809608, PMID 18833002, PMID 21525398, PMID 22495394, PMID 25126421, PMID 25454870, PMID 25688159, PMID 27190628, PMID 27879972, PMID 28851380, PMID 29863979, PMID 32439700, PMID 32513836, PMID 32554615, PMID 33831732, PMID 33942954, PMID 34046035, PMID 34484187, PMID 34773923, PMID 36089578, PMID 36248865, PMID 36326756, PMID 40132910, PMID 42728546
P30CA022453 (2), P30CA051008 (2), 2008 (1), 2009 (1), 2015 (1), 2017 (1), 2019 (1), 2023 (1), P01CA015396 (1), P30CA015083 (1), P30CA015704 (1), P30CA043703 (1), R01CA088972 (1), R01CA129517 (1)